PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF740 conjugate, 0.1mg/mL

Biotium

PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF740 conjugate, 0.1mg/mL

16

Flow Cytometry, ImmunoFluorescence, Western Blot, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin

Research Use Only

Monoclonal

PDL1/2746

0.1 mg/ml

Other Conjugate

CD274

CD274 molecule

ADMIO5, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1, PDL1, hPD-L1, programmed cell death 1 ligand 1, B7 homolog 1, CD274 antigen, PDCD1 ligand 1

IgG2b

Programmed cell death 1 ligand 1

PD-L1 (also known as Programmed Death Ligand 1, CD274, and B7-H1) is one of two cell surface ligands that engage the negative regulatory T cell surface receptor PD-1. PD-L1 is a Type I transmembrane protein expressed on the plasma membrane of cells, such as activated macrophages and some tumor cells. Because binding of PD-1 by PD-L1 has a suppressive effect on the immune system, inhibition of the PD-1/PD-L1 pathway is a major strategy of immune-oncology therapies. PD-L1 is upregulated in certain cancers, and blocking PD-1 or PD-L1 can inhibit cancer growth. Primary antibodies are available purified, or with a selection of fluorescent CF® Dyes and other labels. CF® Dyes offer exceptional brightness and photostability. Note: Conjugates of blue fluorescent dyes like CF®405S and CF®405M are not recommended for detecting low abundance targets, because blue dyes have lower fluorescence and can give higher non-specific background than other dye colors.

Animal

2°C to 8°C,RT

41116100